Clinical Trials Logo

Clinical Trial Summary

Rabies infection is a disease that is caused by a virus and which is transmitted in many countries by rabid animals (dogs, monkeys, bats, etc.) through bites, scratches or licking of wounds. In most cases, humans die from it once the disease has broken out. CV7202 is a new vaccine which has not yet been studied in humans and does not consist of virus protein. Instead, the "building block" for the protein in the form of a so-called messenger RNA (mRNA) will be used. All living organisms have mRNA in their body. mRNA is the carrier of the information that the cells require to form proteins. In this study, mRNA that carries the information for the formation of the rabies virus protein called RABV-G will be injected into the muscle. Following the vaccination, the vaccinated individual's own cells will produce the RABV-G protein. The immune system recognizes the protein and an immune response is triggered. This clinical study will assess the safety, reactogenicity and immunogenicity of CV7202 mRNA-rabies vaccine in healthy adults.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03713086
Study type Interventional
Source CureVac AG
Contact
Status Completed
Phase Phase 1
Start date October 12, 2018
Completion date November 23, 2021

See also
  Status Clinical Trial Phase
Completed NCT03961555 - Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies Phase 2
Completed NCT04644484 - A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety Phase 3
Active, not recruiting NCT05667974 - A Study to Evaluate a PIKA Rabies Vaccine(Vero Cell)for Human Use,Freeze-dried Phase 3
Completed NCT01641315 - Immunogenicity Study of a Reduced (4-dose) Vaccine Schedule and Rabies Immunoglobulins N/A
Completed NCT02238756 - Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy Adults Phase 1
Completed NCT01930357 - Purified Vero Rabies Vaccine-Serum Free Compared to Human Diploid Cell Vaccine in a Pre-exposure Prophylaxis Regimen Phase 2
Completed NCT01680016 - A Randomized, Open-label Study Comparing Two Different Rabies Vaccine Schedules in Chinese Children and Older Adults Phase 3
Completed NCT04019444 - Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects Phase 1
Completed NCT02729168 - Safety Study of Rabies Vaccine INDIRAB® Five Doses (0.5ml) Post Exposure Administered Intramuscularly N/A
Completed NCT02241135 - RNActive® Rabies Vaccine (CV7201) in Healthy Adults Phase 1
Completed NCT01388985 - Simplifying the Rabies Pre-exposure Vaccination Phase 3
Completed NCT04829630 - Immunity Persistence After Abridged Intradermal Rabies PEP N/A
Completed NCT05350735 - Phone Text Message Reminders on Compliance With Human Rabies Post Exposure Prophylaxis Project N/A
Active, not recruiting NCT06132789 - A Clinical Trial of Rabies Vaccine(Human Diploid Cell)for Human Use,Freeze-dried in a Population Aged 10-60 Years Phase 1
Completed NCT02281396 - The Safety Research of Freeze-dried Rabies Vaccine(MRC-5 Cell) in Chinese Humans Phase 1
Completed NCT01466387 - A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults Phase 3
Completed NCT00825305 - Safety and Immunogenicity (Non-inferiority) of a Purified Chick Embryo Cell Vaccine Vaccine Administered in Two Different Schedules (Conventional Versus Abbreviated Schedule) Phase 3
Completed NCT05547815 - Observation on the Immune Persistence of People Aged 10-60 Years Old Immunized With Five Doses of Rabies Vaccine Phase 4
Completed NCT02564471 - Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis. Phase 4
Unknown status NCT01173302 - Persistence of Rabies Antibody 1-5 Years After the Post-exposure Prophylaxis With Vero Cell Antirabies Vaccine and Antibody Response to a Single Booster Dose Phase 4